Register
Login:
Share:
Email Facebook Twitter

GWP Share Chat - RSS Feed

Gw Pharmaceuticals Share Chat (GWP)



Share Price: 445.75Bid: 450.25Ask: 451.00Change: -13.25 (-2.89%)Faller - Gw Pharm.
Spread: 0.75Spread as %: 0.17%Open: 464.00High: 464.75Low: 445.75Yesterday’s Close: 459.00


Share Discussion for Gw Pharm. (GWP)


Thread ViewThread View
Please Login or Register to post messages
Posts per page:


Ddug
Posts: 2,912
Observation
Opinion:No Opinion
Price:62.63
Sold
8 Nov '12
Here some time ago, now in sclp if you are looking for a share that likes to head north, DYOR
 
cashking
Posts: 8,839
Observation
Opinion:No Opinion
Price:62.63
Sp
8 Nov '12
Hasn't seen these levels since march 09 .seriously needs a pick me up management statement gl
Bayviewplot
Posts: 53
Off Topic
Opinion:No Opinion
Price:62.63
Trend setter?
8 Nov '12
Just bought more at the end of the day today to bring down my average and had an identical (odd) amount bought just after - had to check I didn't press the buy button twice!
mulledwine
Posts: 35,667
Off Topic
Opinion:No Opinion
Price:71.50
GWP
16 Oct '12
Valuation: DCF-based valuation of £200m
While the real-world data and cost-effectiveness analysis have no immediate impact
on our valuation or forecasts, they provide further support for our peak sales forecast
for Sativex in MS spasticity of £64m. Greater than expected market share/growth and
new indications for Sativex, clinical progress in cancer pain or developments with
Otsuka (a second US Sativex indication or licensing deal on CNS/cancer candidates
from the research collaboration) represent upside to our base-case valuation.
mulledwine
Posts: 35,667
Off Topic
Opinion:No Opinion
Price:71.50
GWP
16 Oct '12
jange
Posts: 25,142
Off Topic
Opinion:No Opinion
Price:70.00
gwp
12 Oct '12
GW Pharmaceuticals, the British biotech firm, has seen clinical data released by partner Almirall that gives further backing for the efficacy of GW's cannabis-based drug, Sativex.

The results of a study in Germany with 300 patients was released at a major conference in France. The study found that Sativex reduced the symptoms of moderate to severe spasticity due to multiple sclerosis.

The data confirmed that after three months, 41% of patients treated with Sativex, who were resistant to other therapies, showed a clinically relevant response.

The medicine has been proven to be a cost-effective treatment in Germany where Almirall has already made it available, as well as Spain and Denmark.

Next year GW Pharma is expecting the results of Phase III study into Sativex's efficacy as a treatment for cancer pain.

GW's cancer pain clinical programme is being wholly funded by Otsuka Pharmaceutical, which has licensed the US commercialisation rights to this product.

Sativex is licensed to Otsuka in the US, Almirall in Europe (excluding the United Kingdom) and Mexico, Bayer HealthCare in the UK and Canada, Novartis Pharma in Australasia, Asia (excluding Japan and China), Middle East (excluding Israel) and Africa, and Neopharm Group in Israel.
BilkosBuddy
Posts: 511
Observation
Opinion:No Opinion
Price:70.50
GWP
12 Oct '12
, 2012
GW Pharmaceuticals
Positive German Sativex Data Presented at ECTRIMS
RNS Number : 5446O
GW Pharmaceuticals PLC
12 October 2012
Bayviewplot
Posts: 53
Off Topic
Opinion:No Opinion
Price:70.50
First share
11 Oct '12
And as firsts go, it has some odd quirks! Got some hyp's that are a lot better behaved but not as interesting. Happy to hold and top up if it goes lower.
TheOptimist.
Posts: 59
Off Topic
Opinion:No Opinion
Price:69.50
Crumbles
11 Oct '12
Thank you.I am holding my nerve!! and practising patience!! GLA
Crumbles
Posts: 58
Off Topic
Opinion:No Opinion
Price:70.50
Small sells
10 Oct '12
Market manipulation by speculators keeping price down. Watch out for some big buys shortly. This share will rocket when the phase 3 cancer pain trials conclude and FDA approval follows. Hold your nerve!



Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs

Sign up for Live Prices
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.